Cytokines, GM-CSF and IFNγ administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin

Journal of Translational Medicine

Volumn 4, Issue , 2006, Pages

  Apte, Sachin M ^a   Vadhan Raj, Saroj ^a   Cohen, Lorenzo ^a   Bassett, Roland L ^a   Gordon, Ilyssa O ^a   Levenback, Charles F ^a   Ramirez, Pedro T ^a   Gallardo, Stacie T ^a   Patenia, Rebecca S ^a   Garcia, Michael E ^a   Iyer, Revathy B ^a   Freedman, Ralph S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CD14 ANTIGEN; CD64 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR CXCR3; CISPLATIN; COLONY STIMULATING FACTOR; CYTOKINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA1B INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; HLA DR ANTIGEN; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; PACLITAXEL; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TRASTUZUMAB;

ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL COUNT; CHEST TIGHTNESS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DRUG CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; EOSINOPHIL COUNT; FATIGUE; FEMALE; HEMATOLOGICAL PARAMETERS; HEMATOPOIETIC SYSTEM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL MONITORING; IMMUNOMODULATION; LEUKOCYTE ACTIVATION; LEUKOCYTE COUNT; LIVER TOXICITY; MONOCYTE; NEUTROPENIA; NEUTROPHIL COUNT; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RECURRENT CANCER; SCORING SYSTEM; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TUMOR CELL LINE;

EID: 33646233778     PISSN: 14795876     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-4-16     Document Type: Article

References (58)

1. Jemall A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10-30.
2. Ries L: SEER Cancer Statistics Review, 1973-1999. NCl: Bethesda, MD 2002.
3. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334:1-6.
4. Ozols RF, Bundy BN, Fowler J: Randomized phase III study of cisplatin/ paclitaxel versus carboplatin/paclitaxel in optimal stage III epithelial ovarian cancer: A Gynecologic Oncology Group trial (GOG 158). Proc Am Soc Clin Oncol 1999, 18:A 1373.
5. Gore M: Treatment of relapsed epithelial ovarian cancer. 2001:468-476.
6. Eisenhauer EA, Vermorken JB, van Glabbeke M: Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]. Ann Oncol 1997, 8:963-968.
7. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF,Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Trope C: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer. the ICON4/AGOOVAR-2.2 trial. Lancet 2003, 361:2099-2106.
8. Melichar B, Freedman RS: Immunology of the peritoneal cavity: relevance for host-tumor relation. Int J Gynecol Cancer 2002, 12:3-17.
9. Bernasconi S, Matteucci C, Sironi M, Conni M, Colotta F, Mosca M, Colombo N, Bonazzi C, Landoni F, Corbetta G: Effects of granulocyte-monocyte colony-stimulating factor (GM-CSF) on expression of adhesion molecules and production of cytokines in blood monocytes and ovarian cancer-associated macrophages. Int J Cancer 1995, 60:300-307.
10. Triozzi PL, Tucker F, Benzies T, Balcerzak SP: Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor. Bone Marrow Transplant 1996, 18:47-52.
11. Allavena P, Peccatori F, Maggioni D, Erroi A, Sironi M, Colombo N, Lissoni A, Galazka A, Meiers W, Mangioni C: Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells. Cancer Res 1990, 50:7318-7323.
12. Metcalf D, Nicola NA: Actions of the colony-stimulating factors in vivo. In The hemopoietic colony-stimulating factors: from biology to clinical applications New York, Cambridge University Press; 1995: 188-204.
13. Vadhan-Raj S, Broxmeyer HE, Hittelman WN, Papadopoulos NE, Chawla SP, Fenoglio C, Cooper S, Buescher ES, Frenck RWJ, Holian A. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. J Clin Oncol 1992, 10:1266-1277.
14. Vadhan-Raj S, Broxmeyer HE, Hittelman WN, Papadopoulos NE, Chawla SP, Fenoglio C, Cooper S, Buescher ES, Frenck RWJ, Holian A, Perkins RC, Scheule RK, Gutterman JU, Salem P, Benjamin RS: Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: Protection at the progenitor cell level. Classic Papers and Current Comments 2002, 7:848-860.
15. Spitler LE, Grossbard ML, Ernstoff MS, Silver G, Jacobs M, Hayes FA, Soong SJ: Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000, 18:1614-1621.
16. Cortes J, Kantarjian H, O'Brien S, Kurzrock R, Keating M, Talpaz M: GM-CSF can improve the cytogenetic response obtained with interreron-alpha therapy in patients with chronic myelogenous leukemia. Leukemia 1998,12:860-864.
17. Grabstein KH, Urdal DL, Tushinski RJ, Mochizuki DY, Price VL, Cantrell MA, Gillis S, Conlon PJ: Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 1986, 232:506-508.
18. Arellano M, Waller EK: Granulocyte-macrophage-colony-stimulating factor and other cytokines: as adjuncts to cancer immunotherapy, stem cell transplantation, and vaccines. Curr Hematol Rep 2004, 3:424-431.
19. Basak SK, Harui A, Stolina M, Sharma S, Mitani K, Dubinett SM, Roth MD: Increased dendritic cell number and function following continuous in vivo infusion of granulocyte macrophage-colony-stimulating factor and interleukin-4. Blood 2002, 99:2869-2879.
20. Armitage JO: Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1998, 92:4491-4508.
21. Buter J, Pinedo HM: Neoadjuvant chemoimmunotherapy in locally advanced breast cancer: a new avenue to be explored. Curr Oncol Rep 2003, 5:171-176.
22. de Gast GC, Klumpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NC, Sein J, Batchelor D, Nooijen WJ, Schornagel JH: Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin Cancer Res 2000, 6:1267-1272.
23. Ryan CW, Vogelzang NJ, Dumas MC, Kuzel T, Stadler WM: Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials. Cancer 2000, 88:1317-1324.
24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom T, Christian MC, Gwyther SG: New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst 2000, 92:205-216.
25. Kouwenhoven M, Ozenci V, Teleshova N, Hussein Y, Huang YM, Eusebio A, Link H: Enzyme-linked immunospot assays provide a sensitive tool for detection of cytokine secretion by monocytes. Clin Diagn Lab Immunol 2001, 8:1248-1257.
26. Melichar B, Savary C, Kudelka AP, Verschraegen C, Kavanagh JJ, Edwards CL, Platsoucas CD, Freedman RS: Lineage-negative human leukocyte antigen-DR+ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis. Clin Cancer Res 1998, 4:799-809.
27. Liu YJ: Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001, 106:259-262.
28. Sanchez-Torres C, Garcia-Romo GS, Cornejo-Cortes MA, Rivas-Carvalho A, Sanchez-Schmitz G: CD16+ and CD16- human blood monocyte subsets differentiate in vitro to dendritic cells with different abilities to stimulate CD4+ T cells. Int Immunol 2001, 13:1571-1581.
29. Crawford K, Gabuzda D, Pantazopoulos V, Xu J, Clement C, Reinherz E, Alper CA. Circulating CD2+ monocytes are dendritic cells. J Immunol 1999, 163:5920-5928.
30. Gordon I, Freedman RS: Monocytes and Macrophages in epithelial ovarian cancer are deficient FcgR mediated functions. Proc of AACR 2005, 46:.
31. Melichar B, Savary CA, Patenia R, Templin S, Melicharova K, Freedman RS: Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma. Int J Gynecol Cancer 2003, 13:435-443.
32. Gordon IO, Freedman RS: Defective antitumor function of monocyte-derived macrophages from epithelial ovarian cancer patients. Clin Cancer Res 2006, 12:1515-1524.
33. Celia D: Manual of the Functional Assessment of Chronci Illness Therapy (FACIT) Scales, Center on Outcomes, Research and Education (CORE)., Evanston Northwestern Healthcare and Northwestern University; 1997.
34. Cella D, Tulsky D, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J: The functional assessment of cancer therapy scale: development and validation of the general measure. Journal of Clinical Oncology 1993, 11:570-579.
35. Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella D, Mazumdar M: Phase III trial of interferon alpha-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000, 18:2972-2980.
36. Cella D, Zagari MJ, Vandoros C, Gagnon D, Hurtz HJ, Nortier J: Epoetin alpha treatament results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 2003, 2:366-373.
37. de Vries EG, Biesma B, Willemse PH, Mulder NH, Stern AC, Aalders JG, Vellenga E: A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res 1991, 51:116-122.
38. Zanotti KM, Rybicki LA, Kennedy AW, Belinson JL, Webster KD, Kulp B, Peterson G, Markman M: Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 2001, 19:3126-3129.
39. Weiner LM, Li W, Holmes M, Catalano RB, Dovnarsky M, Padavic K, Alpaugh RK: Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects. Cancer Res 1994, 54:4084-4090.
40. Edmonson JH, Hartmann LC, Long HJ, Colon-Otero G, Fitch TR, Jefferies JA, Braich TA, Maples WJ: Granulocyte-macrophage colony-stimulating factor. Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin. Cancer 1992, 70:2529-2539.
41. Melichar B, Hu W, Patenia R, Melicharova K, Gallardo ST, Freedman RS: rIFNgamma-mediated growth suppression of platinum-sensitive and -resistant ovarian tumor cell lines not dependent upon arginase inhibition. J Translational Med 2003, 1:.
42. Ito T, Amakawa R, Inaba M, Ikehara S, Inaba K, Fukuhara S: Differential regulation of human blood dendritic cell subsets by IFNs. J Immunol 2001, 166:2961-2969.
43. Maluish AE, Urba WJ, Longo DL, Overton WR, Coggin D, Crisp ER, Williams R, Sherwin SA, Gordon K, Steis RG: The determination of an immunologically active dose of interferon-gamma in patients with melanoma. J Clin Oncol 1988, 6:434-445.
44. Nathan CF, Horowitz CR, de la Harpe J, Vadhan-Raj S, Sherwin SA, Oettgen HF, Krown SE: Administration of recombinant interferon gamma to cancer patients enhances monocyte secretion of hydrogen peroxide. Proc Natl Acad Sci U S A 1985, 82:8686-8690.
45. Kleinerman ES, Kurzrock R, Wyatt D, Quesada JR, Gutterman JU, Fidler IJ: Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant gamma-interferon. Cancer Res 1986, 46:5401-5405.
46. Malik ST, Knowles RG, East N, Lando D, Stamp G, Balkwill FR: Anti-tumor activity of gamma-interferon in ascitic and solid tumor models of human ovarian cancer. Cancer Res 1991, 51:6643-6649.
47. Welander CE: Interferon in the treatment of ovarian cancer. Semin Oncol 1988, 15:26-29.
48. Pujade-Lauraine E, Guastalla JP, Colombo N, Devillier P, Francois E, Fumoleau P, Monnier A, Nooy M, Mignot L, Bugat R, Marques C, Mousseau M, Netter G, Maloisel F, Larbaoui S, Brandely M: Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 1996, 14:343-350.
49. Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, Denison U, Muller-Holzner E, Marth C: Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 2000, 82:1138-1144.
50. Wing EJ, Magee DM, Whiteside TL, Kaplan SS, Shadduck RK: Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients. Blood 1989, 73:643-646.
51. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000, 6:443-446.
52. Oppenheim J, Fujiwara H: The role of cytokines in cancer. Cytokine Growth Factor Rev 1996, 7:279-288.
53. Lazzeri E, Romagnani P: CXCR3-binding chemokines: novel multifunctional therapeutic targets. Curr Drug Targets Immune Endocr Metabol Disord 2005, 5:109-118.
54. Moore BB, Arenberg DA, Addison CL, Keane MP, Polverini PJ, Strieter RM: CXC chemokines mechanism of action in regulating tumor angiogenesis. Angiogenesis 1998, 2:123-134.
55. Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, Lin W, Boyd JG, Moser B, Wood DE, Sahagan BG, Neote K: Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998, 187:2009-2021.
56. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23:549-555.
57. Bingle L, Brown NJ, Lewis CE: The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002, 196:254-265.
58. Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J: Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004, 22:3120-3125.